MannKind (MNKD) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026Growth outlook and commercial performance
Three growth engines for 2027: FUROSCIX ReadyFlow, Afrezza, and expanded United Therapeutics programs; nintedanib DPI represents a longer-term IPF opportunity.
Revenue CAGR was 42% over the past five years, driven by royalties, commercial collaboration revenue, FUROSCIX, and Afrezza; Q4 profitability and record revenue were expected.
Q4 revenue was forecast at ~$38 million, subject to quarter-end demand trends.
FUROSCIX ReadyFlow
ReadyFlow received approval in Q3; ~75% of FUROSCIX shipments had converted, while 90% of community demand prescriptions were for ReadyFlow.
Four target settings span worsening at home, emergency departments, inpatient IV diuretics, and post-discharge readmission; each represents nearly 1 million patients annually.
Hospital adoption had slowed, with expansion planned; inpatient discharge and readmission prevention were identified as major growth opportunities.
Afrezza and pediatric initiatives
Pediatric Afrezza adoption was strong: new-to-brand prescriptions rose 80%, about one in four patients at quarter-end were pediatric, and pediatric market share was 2x adult share in the first 90 days.
In 2027, plans include refocusing sales efforts on adults, expanding cardiovascular reach, and continuing pediatric support; a two-unit cartridge is also planned.
INHALE-1ST had ~35 participants; the goal is 100 by mid-2027 and a data readout, testing inhaled insulin in newly diagnosed children.
Inhale IQ, an inhaler adapter integrating dose tracking with CGM data, was being submitted to the FDA, with a launch targeted for 2027.
Latest events from MannKind
- ReadyFlow accelerates, pediatric AFREZZA gains traction, and MNKD-201 advances toward phase II.MNKD
UBS Global Biopharma Conference 2026 - Q3 revenue rose 24% as commercial launches advanced, with Q4 profitability expected.MNKD
Q3 2026 - IPF pipeline advances as ReadyFlow and TYVASO DPI support growth and diversification.MNKD
Chardan's 10th Annual Healthcare Conference - Afrezza pediatric launch, FUROSCIX ReadyFlow, and IPF 201 progress drive growth focus.MNKD
H.C. Wainwright 28th Annual Global Investment Conference - Q2 2026 revenue up 43% to $109.4M, driven by Afrezza pediatric and FUROSCIX launches.MNKD
Q2 2026 - Nintedanib DPI showed strong safety and efficient lung delivery in IPF, supporting Phase 2 trials.MNKD
Study result - FDA approved FUROSCIX ReadyFlow, enabling rapid at-home IV-equivalent diuretic therapy.MNKD
FDA announcement - Q4 and FY 2025 revenues surged, driven by FUROSCIX and Afrezza, with major 2026 catalysts ahead.MNKD
Q4 2025 - Q1 revenue up 18% to $78.4M, net income up 24%, driven by Tyvaso DPI and Afrezza growth.MNKD
Q1 2025